Acute Ischemic Stroke Market, By Therapeutics, By Distribution Channel, By Geography

Global acute ischemic stroke (AIS) market is estimated to be valued at US$ 9.21 Bn in 2023, and is expected to exhibit a CAGR of 4.0% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 9.21 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	4.00%	2030 Value Projection:	US$ 12.12 Bn

Figure 1. Global Acute Ischemic Stroke (AIS) Market Share (%), By Therapeutics, 2023

Acute ischemic stroke (AIS) occurs when blood flow through a brain artery is obstructed by a clot, which is a thickened mass of blood. Clots are classified as either thrombotic or embolic depending on where these form in the body. The most common type of stroke is a thrombotic stroke thatoccurs when a clot forms within a brain artery. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from another part of the body such as the heart, and travels through the bloodstream before becoming lodged in a narrower vessel in the brain. Large vessel occlusion (LVO) is responsible for nearly half of all acute ischemic strokes. LVO is the most serious and debilitating type of stroke because the clot blocks large arteries, and prevents blood flow to essential parts of the brain.

Market Dynamics

Increasing inorganic growth strategies such as partnership by key market players, in order to expand their product portfolio is expected to drive the global acute ischemic stroke (AIS) market growth over the forecast period. For instance, in December 2021, Simcere Pharmaceutical Group Ltd, a biotechnology company, and Avilex Pharma (Avilex), a clinical-stage biotechnology company that focuses on developing innovative medicines for neurological disorders, announced a strategic regional licensing partnership to develop and commercialize medicines that target the postsynaptic density protein 95 (PSD-95) to treat acute ischemic stroke (AIS) and other neurological conditions in greater China. The agreement granted Simcere Pharmaceutical Group Ltd an exclusive regional license to develop and commercialize AVLX-144, Avilex's 2-ready dimeric PSD-95 inhibitor, for the treatment of AIS and other neurological conditions. AVLX-144 is a dimeric peptide-like drug candidate for the treatment of AIS that targets the intracellular scaffolding protein- PSD-95. AVLX-144 is an extensively optimized dimeric PSD-95 inhibitor and a clinical lead candidate for the treatment of acute conditions such as AIS and subarachnoid hemorrhage (SAH).

Key features of the study:

• This report provides an in-depth analysis of the global acute ischemic stroke (AIS) market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global acute ischemic stroke (AIS) market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include F.Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Bayer AG, Pfizer Inc., Biogen, DAIICHI SANKYO COMPANY, LIMITED, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, SanBio Co,Ltd., Athersys, Inc., Abbott, Sanofi, ZZ Biotech, Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., NoNO Inc., AliveCor, Inc., Amgen Inc., Genentech USA, Inc., and DiaMedica Therapeutics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global acute ischemic stroke (AIS) market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute ischemic stroke (AIS) market

Acute Ischemic Stroke (AIS) Market Detailed Segmentation:

• By Therapeutics:
  • Tissue Plasminogen Activator
  • Anticoagulant
  • Antiplatelet
  • Antihypertensive
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles
  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Pfizer Inc.
  • Biogen
  • DAIICHI SANKYO COMPANY, LIMITED
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • SanBio Co,Ltd.
  • Athersys, Inc.
  • Abbott
  • Sanofi
  • ZZ Biotech
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co., Inc.
  • NoNO Inc.
  • AliveCor, Inc.
  • Amgen Inc.
  • Genentech USA, Inc.
  • DiaMedica Therapeutics, Inc.